# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Geronimo (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI016-SYN
- Date: 2026-09-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Roberta Whitehorse-Lindgren, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Eleven-week review: therapy, sertraline, drinking and falls. **S**

## History of present illness

Geronimo returns eleven weeks after intake, with the interpreter. He has had eight sessions of cognitive processing therapy; he missed one when he had bronchitis three weeks ago, which has cleared without antibiotics. He has taken sertraline 25 mg for five weeks without nausea or dizziness. The sodium test planned for two to four weeks after starting was not done: it was not ordered at the sick visit, and today's test is the first. Nightmares come about twice a week and he sleeps five or six hours. He takes a single drink on one or two evenings a week and has had no heavy evening since the last visit. He has not fallen. **S**

| Element | Detail |
|---|---|
| Therapy | Eight of twelve sessions; one missed when ill |
| Sertraline | 25 mg for five weeks; no side effects |
| Sodium | 137 mmol/L |
| Drinking | One drink on one or two evenings a week |
| PCL-5 | 35 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Psychiatric | Positive | Nightmares about twice a week; mood lighter; no thoughts of suicide |
| Respiratory | Negative | Cough gone |
| Neurological | Negative | No dizziness, confusion or headache |
| Gastrointestinal | Negative | No nausea, bleeding or black stools |

4 systems reviewed. **S**

## Current medications

- Thiamine 100 mg oral tablet, one tablet daily **S**
- Naltrexone 50 mg oral tablet, one tablet daily; carries a wallet card saying that naltrexone blocks opioid pain medicines **S**
- Sertraline 50 mg oral tablet, one tablet each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 130/78 mmHg; pulse 72 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 67.2 kg; BMI 22.5 kg/m². All vital signs are synthetic.

PCL-5: 35; PHQ-9: 7; Sodium: 137 mmol/L; AST: 33 U/L; ALT: 27 U/L; GGT: 63 U/L (high); PEth (alcohol marker): 41 ng/mL (high). All results are synthetic.

## Change since baseline

- PCL-5: 56 at baseline, 35 at this visit **S**
- PHQ-9: 11 at baseline, 7 at this visit **S**
- Sodium: 139 mmol/L at baseline, 137 mmol/L at this visit **S**
- AST: 58 U/L (high) at baseline, 33 U/L at this visit **S**
- ALT: 36 U/L at baseline, 27 U/L at this visit **S**
- GGT: 112 U/L (high) at baseline, 63 U/L (high) at this visit **S**
- PEth (alcohol marker): 236 ng/mL (high) at baseline, 41 ng/mL (high) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 130/78 seated and 128/76 standing; pulse 72; weight 67.2 kg |
| Mental status | Calm and warm; speaks more of his horses and cattle; no thoughts of suicide or of harming anyone |
| Gait | Steady; Timed Up and Go 12 seconds |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Post-traumatic stress disorder, chronic** (F43.12). PCL-5 35, from 56: a meaningful fall of 21 points. Sodium 137 mmol/L on sertraline. Safety reviewed: no thoughts of suicide or self-harm. **S**
   - Sertraline 50 mg each morning.
   - Finish cognitive processing therapy.
   - Sodium again only if he has symptoms of low sodium or another medicine is added.
2. **Alcohol use disorder, moderate** (F10.20). PEth 41 ng/mL, from 236, agrees with his report of occasional single drinks; liver tests near normal. **S**
   - Continue naltrexone and thiamine.
3. **History of falling** (Z91.81). No falls; no orthostatic drop on sertraline. **S**
   - Continue balance and strength exercises.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PTSD symptom severity (PCL-5) | Baseline, then every visit during treatment | Completed today | 35, from 56 |
| Self-management | Trauma-focused psychotherapy (cognitive processing therapy), sessions attended | Weekly for twelve sessions | Completed today | Eight of twelve sessions; one missed during bronchitis |
| Survey | Depressive symptoms (PHQ-9) | Baseline, then monthly during active treatment | Completed today | 7, from 10; item 9 scored 0 |
| Survey | Suicide-risk review, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; 988 card carried |
| Self-management | Drinking since the last visit, against his own goal | Every visit | Completed today | One drink on one or two evenings a week; no heavy evening |
| Laboratory | Liver tests (AST, ALT, GGT) on naltrexone | Before starting, at four to six weeks, then every three to six months | Completed today | AST 33, ALT 27, GGT 63 U/L |
| Laboratory | PEth, a blood marker of drinking over the past two to four weeks | At baseline and every one to three months during treatment, with consent | Completed today | 41 ng/mL, from 236 |
| Medication safety | Naltrexone safety: opioid use, nausea, wallet card | Every visit | Completed today | No opioid use; he declined a codeine cough syrup during the bronchitis |
| Medication safety | SSRI safety: sodium, bleeding, falls and side effects | Sodium within the first month in older adults; review at each dose change | Deferred | The sodium check due two to four weeks after starting sertraline was missed: it was not ordered at the sick visit two weeks after the start, the one visit in that window. Done today at five weeks: 137 mmol/L, so no harm resulted, and he had no symptoms of low sodium. Corrective action: a laboratory-only visit is booked two weeks after any future SSRI dose change, and the clinic's SSRI order set now prompts the sodium check |
| Medication safety | Prazosin for nightmares | When nightmares persist despite first-line treatment | Not indicated | Nightmares falling with therapy and sertraline; not needed now |
| Examination | Falls and gait (Timed Up and Go), orthostatic blood pressure | At intake and every visit after a fall | Completed today | Timed Up and Go 12 seconds; standing pressure 128/76; no falls |
| Self-management | Traditional healing alongside clinic care, at his choice | Every visit | Completed today | His choice; nothing asked |

## Goal progress

- Sleep most nights with nightmares no more than once a week. In progress; target 2026-10-28. **S**
- Lower PTSD symptoms by a meaningful amount (PCL-5 down at least 10 to 20 points). In progress; target 2026-10-28. **S**
- Drink no more than one drink on any day, and no drinking before riding. In progress; target 2026-10-28. **S**
- No further falls. In progress; target 2026-10-28. **S**

## Medication changes

- Stopped: Sertraline 25 mg oral tablet, one tablet each morning, raised to 50 mg after the sodium check **S**
- Started: Sertraline 50 mg oral tablet, one tablet each morning **S**

## Guideline basis

- VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder (2023), United States Department of Veterans Affairs and Department of Defense (synopsis: Ann Intern Med 2024;177(3):363-374)
- Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults (2017), American Psychological Association
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (Am J Psychiatry 2018;175(1):86-90)
- The Healthcare Professional's Core Resource on Alcohol (2026), National Institute on Alcohol Abuse and Alcoholism
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- Special General Memorandum 94-08: Statement of Policy for the Traditional Cultural Advocacy Program (1994), Indian Health Service
- American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023), American Geriatrics Society (Journal of the American Geriatrics Society)
- Falls Prevention in Community-Dwelling Older Adults: Interventions (2024), U.S. Preventive Services Task Force

## Follow-up

- Wellness visit in two weeks. Sixteen-week review in five weeks with PEth, liver tests, PCL-5, PHQ-9 and AUDIT. Call the clinic or 988 at any hour. **S**
- Next scheduled visit 2026-10-07: initial annual wellness visit. **S**
